26272-83-3

Basic information

• Product Name: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER
• Synonyms: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER;3-Oxetanyl tosylate;3-(tosyloxy)oxetane;3-Oxetanyl p-toluenesulfonate, 96%;3-Ts-oxetan;oxetan-3-yl 4-Methylbenzene-1-sulfonate;3-Oxetanyl p-Toluenesulfonate
• CAS NO: 26272-83-3
• Molecular Formula: C₁₀H₁₂O₄S
• Molecular Weight: 228.26488
• Product Categories: Heterocycles
• Mol File: 26272-83-3.mol
• Article Data: 21

Chemical Properties

• Melting Point: 81.0 to 86.0 °C
• Boiling Point: 372℃
• Flash Point: 179°(354°F)
• Appearance: /
• Density: 1.34
• Vapor Pressure: 2.18E-05mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(26272-83-3)
• EPA Substance Registry System: TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER(26272-83-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 26272-83-3(Hazardous Substances Data)

Usage

General Description

Toluene-4-sulfonic acid oxetan-3-yl ester is a chemical compound created by esterifying oxetan-3-yl with toluene-4-sulfonic acid. It is used as a high-purity intermediate for the production of pharmaceuticals, agrochemicals, and specialty chemicals. TOLUENE-4-SULFONIC ACID OXETAN-3-YL ESTER has various industrial applications, including as a reagent for organic synthesis, as a stabilizer for chlorine-containing compounds, and as a solvent for various resins and polymers. Its high purity and stability make it a valuable building block for the synthesis of complex molecules in the pharmaceutical and chemical industries.

InChI:InChI=1/C10H12O4S/c1-8-2-4-10(5-3-8)15(11,12)14-9-6-13-7-9/h2-5,9H,6-7H2,1H3

Upstream product

• 7748-36-9 oxetan-3-ol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 81764-67-2 3-Azidooxetane 
• 6735-33-7 3-phenoxyoxetane 

Relevant articles and documents

Synthesis of Electron-Deficient Oxetanes. 3-Azidooxetane, 3-Nitrooxetane, and 3,3-Dinitrooxetane

A facile synthesis of 3-hydroxyoxetane is described and is based on the addition of acetic acid to epichlorohydrin, protection of the resulting primary alcohol as an acetal, basic acetate hydrolysis and ring closure, and removal of the protecting group. 3-Azidooxetane was prepared from 3-(tosyloxy)oxetane and sodium azide.Reduction of the azide with triphenylphosphine or hydrogen gave 3-aminooxetane, and oxidation of the amine with m-chloroperbenzoic acid gave 3-nitrooxetane.Oxidative nitration or reaction with tetranitromethane gave 3,3-dinitrooxetane. 3-Azidooxetane and 3,3-dinitrooxetane were polymerized with Lewis acids.

Fused tricyclic derivative as FGFR4 inhibitor

The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.